GenSight Biologics S.A. (EPA:SIGHT)
France
· Delayed Price · Currency is EUR 0.2650
+0.0365 (15.97%)
Apr 24, 2025, 5:35 PM CET
GenSight Biologics Revenue
In the year 2024, GenSight Biologics had annual revenue of 2.63M EUR, down -11.44%. GenSight Biologics had revenue of 897.00K in the half year ending December 31, 2024, with 46.09% growth.
Revenue
2.63M
Revenue Growth
-11.44%
P/S Ratio
11.32
Revenue / Employee
164.06K
Employees
16
Market Cap
29.72M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.63M | -339.00K | -11.44% |
| Dec 31, 2023 | 2.96M | -1.90M | -39.08% |
| Dec 31, 2022 | 4.87M | -2.84M | -36.89% |
| Dec 31, 2021 | 7.71M | 269.00K | 3.62% |
| Dec 31, 2020 | 7.44M | 2.53M | 51.53% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| EssilorLuxottica Société anonyme | 26.51B |
| Sanofi | 44.29B |
| Sartorius Stedim Biotech | 2.86B |
| bioMérieux | 3.98B |
| Eurofins Scientific SE | 6.95B |
| Ipsen | 3.57B |
| Virbac | 1.40B |
| emeis Société anonyme | 5.64B |
GenSight Biologics News
- 16 days ago - GenSight Biologics Announces the Filing of its 2024 Universal Registration Document - Business Wire
- 17 days ago - GenSight Biologics Reports Cash Position as of March 31, 2025, and Provides Business Update - Business Wire
- 5 weeks ago - GenSight Biologics Confirms Definitive Full-Year 2024 Consolidated Financial Results Are in Line with Estimates - Business Wire
- 5 weeks ago - GenSight Biologics Announces LUMEVOQ® Scientific Updates at NANOS 2025 - Business Wire
- 7 weeks ago - GenSight Biologics S.A. reports FY results - Seeking Alpha
- 2 months ago - GenSight Biologics Reports Estimated Full-Year 2024 Consolidated Financial Results - Business Wire
- 2 months ago - GenSight Biologics Announces Five-Year Efficacy and Safety Results for LUMEVOQ® Gene Therapy at the Conclusion of the REFLECT Study - Business Wire
- 3 months ago - GenSight Biologics Reports End-of-Year Cash Position and Provides Business Update - Business Wire